Navidea Receives Orphan Drug Designation from FDA for Use of Lymphoseek® in Head and Neck Cancers Sep 18, 2014
Navidea Announces Second Quarter 2014 Financial Results; Total Revenues Grow to $1.1 Million Aug 6, 2014
Navidea Biopharmaceuticals to Announce Second Quarter 2014 Financial Results on August 6, 2014 Jul 29, 2014
Navidea Joins Essex Woodland’s Rheumco to Develop Radiopharmaceuticals for Detection and Treatment of Arthritic Diseases Jul 16, 2014
Navidea to Webcast Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers July 8, 2014 Jul 2, 2014
Navidea Biopharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference Jun 17, 2014
U.S. FDA Approves Navidea Biopharmaceuticals’ Lymphoseek® (technetium Tc 99m tilmanocept) Injection for Expanded Use in Head and Neck Cancer Sentinel Lymph Node Biopsy Jun 13, 2014
Navidea Biopharmaceuticals’ Lymphoseek® (technetium Tc 99m tilmanocept) Injection Demonstrates Preferential Accumulation in Tumor-Positive Sentinel Lymph Nodes in Post-Hoc Analysis Jun 11, 2014
